Search results
BMS reports four-year data from psoriasis treatment extension trial
Clinical Trials Arena via Yahoo Finance· 11 hours agoBristol Myers Squibb (BMS) has revealed four-year data from the POETYK PSO long-term extension (LTE)...
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst - AbbVie...
Benzinga· 2 hours agoCantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target....
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
The Wall Street Journal· 7 days agoHEALTH NEWS Bristol Myers Squibb said on Friday that its trial evaluating a combination of cancer...
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously...
Benzinga· 1 day agoWednesday, the FDA granted accelerated approval to Bristol Myers Squibb Co’s BMY Breyanzi...
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Zacks via Yahoo Finance· 1 day agoBristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy...
TD Cowen maintains $67 target on Bristol-Myers Squibb By Investing.com
Investing.com· 24 hours agoOn Thursday, TD (TSX:TD) Cowen sustained its Hold rating on shares of Bristol-Myers Squibb Co....
FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe US Food and Drug Administration (FDA) has granted accelerated approval for Bristol Myers...
Zacks Research Comments on Bristol-Myers Squibb’s FY2024 Earnings (NYSE:BMY)
ETF DAILY NEWS· 4 days agoBristol-Myers Squibb (NYSE:BMY – Free Report) – Equities research analysts at Zacks Research issued their FY2024 earnings estimates for shares of Bristol-Myers Squibb in a report issued on Thursday ...
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Zacks via Yahoo Finance· 2 days agoBristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it...
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration...
Morningstar· 2 days agoBristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma 95.7% of patients responded to Breyanzi in the TRANSCEND FL trial Breyanzi provided sustained clinical